12 events about "AstraZeneca"

3 August 2026, 10:00

AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group

Sources

International

9 July 2026, 14:05

AstraZeneca announced the failure of a drug for a rare heart condition, causing a 9% drop in the company's shares.

Sources

International

24 February 2026, 17:39

Pascal Soriot, the CEO of AstraZeneca, was paid £17.7 million in 2025. There is a possibility that in 2026 he will earn approximately £20 million.

Sources

Current Affairs

10 February 2026, 13:23

AstraZeneca recorded a net profit of 10.2 billion dollars in 2025, with a 45% increase due to sales of cancer drugs.

Sources

International

11 October 2025, 08:16

AstraZeneca has announced significant reductions for medications sold in the United States, following an agreement made with the Trump administration.

Sources

International

6 October 2025, 12:44

AstraZeneca has signed a 555 million dollar agreement with Algen for the development of therapies based on Crispr technology, specialized in artificial intelligence.

Sources

Economy

30 September 2025, 09:18

AstraZeneca aims for a full listing in New York, but remains headquartered in the United Kingdom.

Sources

International

14 September 2025, 06:12

AstraZeneca has announced the suspension of a 200 million pound investment in the research center in Cambridge, affecting 1,000 jobs.

Sources

Economy

23 July 2025, 08:20

AstraZeneca will invest 50 billion dollars to expand manufacturing and research in the US, including a new plant in Virginia for anti-obesity treatments.

Sources

+2

International

3 July 2025, 08:05

AstraZeneca could leave the London Stock Exchange over dissatisfaction with regulations, which would significantly affect the FTSE 100 index.

Sources

Economy

2 June 2025, 06:41

An experimental pill from AstraZeneca has shown a 56% reduction in the risk of breast cancer progression, according to a study presented at ASCO

Sources

Health

19 March 2024, 12:18

AstraZeneca is buying Fusion Pharmaceuticals, a Canadian company specializing in radioconjugation cancer treatments, for $2.4 billion.

Sources

Health

Personalized news feed, AI-powered search, and notifications in a more interactive experience.

app preview

google play badge